Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 513-520

  Assouline, Sarit ^a   Meyer, Ralph ^b   Infante Rivard, Claire ^c   Connors, Joseph M ^d   Belch, Andrew ^e   Crump, Michael ^f   Kouroukis, C Tom ^g   Eisenhauer, Elizabeth ^b  

^a MCGILL UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

International Workshop Criteria; Lymphoma; RECIST; Response criteria

Indexed keywords

BORTEZOMIB; CISPLATIN; DEXAMETHASONE; FLAVOPIRIDOL; GEMCITABINE;

ARTICLE; CANCER REGRESSION; CANCER SIZE; CLINICAL TRIAL; CYTOMETRY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; EVALUATION STUDIES; HUMANS; INTERNATIONAL COOPERATION; LYMPHOMA; TREATMENT OUTCOME;

EID: 33947629719     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601078126     Document Type: Article

References (23)

1. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S. and Rubinstein, L. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 92, pp. 205-216.
2. Eisenhauer, E. A., Bonetti, M. and Gelber, R. D. (2000) Principles of clinical trials. Textbook of Medical Oncology, pp. 99-136. Martin Dunitz, London
3. James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A. and Therasse, P. (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst, 91, pp. 523-528.
4. (1979) WHO handbook for reporting results of cancer treatment, WHO, Geneva, Switzerland
5. Erasmus, J. J., Gladish, G. W., Broemeling, B. S., Truong, M. T., Herbst, R. S. and Munden, R. F. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol, 21, pp. 2574-2582.
6. Cheson, B., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
7. Cheson, B. D., Pfistner, B., Juweid, M. E., Horning, S. J., Coiffier, B., Gascoyne, R. D. and Fisher, R. I. (2006) International Harmonization Project. Recommendations for revised response criteria for malignant lymphoma. J Clin Oncol, 24, p. 7507.
8. Cheson, B. D., Pfistner, B., Juweid, M. E., Specht, L., Rosen, S. T. and Gascoyne, R. (2005) Revised response criteria for malignant lymphomas. From the members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma. Blood, 106
9. Dorfman, R. E., Alpern, M. B., Gross, B. H. and Sandler, M. A. (1991) Upper abdominal lymph nodes: Criteria for normal size determined with CT. Radiology, 180, pp. 319-322.
10. Glazer, G. M., Gross, B. H., Quint, L. E., Francis, I. R., Bookstein, F. I. and Orringer, M. B. (1985) Normal mediastinal lymph nodes: Number and size according to American Thoracic Society mapping. Am J Roentgenol, 144, pp. 261-265.
11. Steinkamp, H. J., Hosten, N., Richter, C., Schedel, H. and Felix, R. (1994) Enlarged cervical lymph nodes at helical CT. Radiology, 191, pp. 795-798.
12. Strijk, S. P., Boetes, C., Bogman, M. J., Pauw, B E del and Wobbes, T. (1987) The spleen in non-Hodgkin lymphoma: Diagnostic value of computed tomography. Acta Radiol, 28, pp. 139-144.
13. Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D. and Myers, R. (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 21, pp. 1740-1745.
14. Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J. and Myers, R. (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol, 14, pp. 1762-1767.
15. Crump, M., Baetz, T., Couban, S., Belch, A., Marcellus, D. and Howson-Jan, K. (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer, 101, pp. 1835-1842.
16. Assouline, S., Belch, A., Sehn, L., Kouroukis, C. T., Gascoyne, R., Meyer, R. and Eisenhauer, E. (2003) A phase II trial of bortezomib in patients with mantle cell lymphoma. Blood, 102
17. McKinnon, A. (2000) A spreadsheet for the calculation of comprehensive statistics for the assessment of diagnostic tests and inter-rater agreement. Computers Biol Med, 30, pp. 127-134.
18. Czuczman, M. S., Koryzna, A., Mohr, A., Stewart, C., Donahue, K. and Blumenson, L. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol, 23, pp. 694-704.
19. Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J. and Grillo-Lopez, A. J. (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol, 22, pp. 4711-4716.
20. Darby, A. and Gribben, J. G. (2005) Follicular lymphoma: Quantitation of minimal residual disease by PCR of the t(14;18) translocation. Methods Mol Med, 115, pp. 315-331.
21. Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M., Poor, C., Janicek, M. J. and Shipp, M. A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol, 20, pp. 1288-1294.
22. Pott, C., Schrader, C., Gesk, S., Harder, L., Tiemann, M. and Raff, T. (2006) Quantitative assessment of molecular remission following high-dose therapy with autologous stem cell transplantation predicts long term remission in mantle cell lymphoma. Blood, 107, pp. 2271-2278.
23. Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y. and Wooldridge, J. E. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 23, pp. 1-10.